Transplantation of fetal hematopoietic stem cells in utero: the creation of hematopoietic chimeras

Transplantation of normal, immature, fetal hematopoietic cells into a preimmune fetal recipient with a congenital hemoglobinopathy may allow partial reconstitution of normal hemoglobin production without the complications associated with postnatal bone marrow transplantation (immunosuppression and the occurrence of graft versus host disease). In order to test this hypothesis the naturally occurring polymorphism at the beta-hemoglobin locus of the sheep was used as a marker for engraftment and hematopoietic chimerism. Intraperitoneal injection of allogeneic fetal stem cells into normal fetal lambs resulted in hematopoietic chimerism in three of four surviving recipients. This chimerism has been sustained for 6 months after birth and 9 months after engraftment, without evidence of graft versus host disease, and without the use of immunosuppressive therapy.     

Progress toward human gene therapy

Current therapies for most human genetic diseases are inadequate. In response to the need for effective treatments, modern molecular genetics is providing tools for an unprecedented new approach to disease treatment through an attack directly on mutant genes. Recent results with several target organs and gene transfer techniques have led to broad medical and scientific acceptance of the feasibility of this "gene therapy" concept for disorders of the bone marrow, liver, and central nervous system; some kinds of cancer; and deficiencies of circulating enzymes, hormones, and coagulation factors. The most well-developed models involve alteration of mutant target genes by gene transfer with recombinant pathogenic viruses in order to express new genetic information and to correct disease phenotypes--the conversion of the swords of pathology into the plowshares of therapy.     

Bone marrow transplantation

The goals in bone marrow transplantation are its application to the treatment of diseases arising in the blood-forming tissues of man. Techniques for procuring and grafting marrow are of the needle-and-syringe type and are based on the normal physiological processes in which stem cells circulate through blood and other fluids of the mammalian organism. Destruction of bone marrow by irradiation, chemicals, or unknown agencies provides the immediate experimental system for demonstrating the therapeutic value of marrow transplants. Genetic diseases characterized by abnormal marrow function are also modifiable by grafts of blood-forming tissues. Studies with identical twins are critical experiments for showing the clinical value of grafts, even though the transplanted cells cannot be identified by the usual marker techniques. Among the best results seen with marrow grafting is the presumed cure of certain rare hereditary immune-deficiency disorders of children. A major problem in bone marrow transplantation-one that delays its wider clinical application-is the immune reaction from cells growing out of the foreign transplant which attack the host (the graft-versus-host reaction). Attempts to use a graft-versus-host response to eliminate tumor cells is a part of the marrow research program. The history of the processes that led to some of the achieved goals in marrow grafting shows the usual multicentric origin of an idea. Certain individuals play critical roles in developing the idea. Finally, a body of knowledge is accumulated that opens up or limits prospects for the future. In bone marrow transplantati on, future achievements will depend in part on the progress that is made in the areas of cell separation, bone marrow banking, and tissue culture.     

Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation

Natural killer cell (NK) receptors for major histocompatibility complex (MHC) class I influence engraftment and graft-versus-tumor effects after allogeneic bone marrow transplantation. We find that SH2-containing inositol phosphatase (SHIP) influences the repertoire of NK receptors. In adult SHIP-/- mice, the NK compartment is dominated by cells that express two inhibitory receptors capable of binding either self or allogeneic MHC ligands. This promiscuous repertoire has significant functional consequences, because SHIP-/- mice fail to reject fully mismatched allogeneic marrow grafts and show enhanced survival after such transplants. Thus, SHIP plays an important role in two processes that limit the success of allogeneic marrow transplantation: graft rejection and graft-versus-host disease.     

Prospects for human gene therapy

Procedures have now been developed for inserting functional genes into the bone marrow of mice. The most effective delivery system at present uses retroviral-based vectors to transfer a gene into murine bone marrow cells in culture. The genetically altered bone marrow is then implanted into recipient animals. These somatic cell gene therapy techniques are becoming increasingly efficient. Their future application in humans should result in at least partial correction of a number of genetic disorders. However, the safety of the procedures must still be established by further animal studies before human clinical trials would be ethical.     

Transplantation of allogenic bone marrow in canine cyclic neutropenia

Transplantation of normal bone marrow cells to a gray collie dog with cyclic neutropenia resulted in normal granulocytopoiesis. The finding suggests that cyclic neutropenia occurs because the hematopoietic stem cells are defective. Because of the similarity of human and canine cyclic neutropenia, it also suggests that the human disease may be curable by marrow transplantation.     

Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation

The twitcher mouse is an animal model of galactosylceramidase deficiency, comparable to Krabbe's disease, a lysosomal storage disease in humans. As in most lysosomal storage diseases, neurological deterioration is a prominent feature of the disease in these mice. Transplantation of enzymatically normal congenic bone marrow was earlier found to result in prolonged survival and increased levels of galactosylceramidase in the visceral organs of twitcher mice. It is now reported that bone marrow transplantation results in increased galactosylceramidase levels in the central nervous system (CNS). Concomitantly, the levels of psychosine, a highly toxic lipid that progressively accumulates in the CNS of untreated twitcher mice, stabilized at much lower levels in the CNS of treated twitcher mice. Histologically, a gradual disappearance of globoid cells, the histological hallmark of Krabbe's disease, and the appearance of foamy macrophages capable of metabolizing the storage product were seen in the CNS. By immunohistochemical labeling it was demonstrated that these foamy macrophages were of donor origin. The infiltration of enzymatically competent, donor-derived macrophages was accompanied by extensive remyelination in the CNS. It is concluded that after bone marrow transplantation, donor-derived macrophages infiltrate the affected brain tissue and are capable of inducing a partial reversal of the enzyme deficiency.     

Gene therapy for human genetic disease?

In our view, gene therapy may ameliorate some human genetic diseases in the future. For this reason, we believe that research directed at the development of techniques for gene therapy should continue. For the foreseeable future, however, we oppose any further attempts at gene therapy in human patients because (i) our understanding of such basic processes as gene regulation and genetic recombination in human cells is inadequate; (ii) our understanding of the details of the relation between the molecular defect and the disease state is rudimentary for essentially all genetic diseases; and (iii) we have no information on the short-range and long-term side effects of gene therapy. We therefore propose that a sustained effort be made to formulate a complete set of ethicoscientific criteria to guide the development and clinical application of gene therapy techniques. Such an endeavor could go a long way toward ensuring that gene therapy is used in humans only in those instances where it will prove beneficial, and toward preventing its misuse through premature application. Two recent papers have provided new demonstrations of directed genetic modification of mammalian cells. Munyon et al. (44) restored the ability to synthesize the enzyme thymidine kinase to thymidine kinase-deficient mouse cells by infection with ultraviolet-irradiated herpes simplex virus. In their experiments the DNA from herpes simplex virus, which contains a gene coding for thymidine kinase, may have formed a hereditable association with the mouse cells. Merril et al. (45) reported that treatment of fibroblasts from patients with galactosemia with exogenous DNA caused increased activity of a missing enzyme, alpha-D-galactose-l-phosphate uridyltransferase. They also provided some evidence that the change persisted after subculturing the treated cells. If this latter report can be confirmed, the feasibility of directed genetic modification of human cells would be clearly demonstrated, considerably enhancing the technical prospects for gene therapy.     

Immunization with skin isografts taken from tolerant mice

Skin isografts from mice that were immunologically tolerant to allogeneic tissue had the ability to immunize isogeneic recipients against subsequent skin allografts. The immunizing isografts showed no gross signs of rejection themselves and appeared to be only the vehicles for transplantation antigen. It seems likely that allogeneic leukocytes derived from the spleen and bone marrow cells used to confer tolerance were contained in the skin of the tolerant mice and were transferred by the skin isografts in sufficient numbers to stimulate transplantation immunity.     

Gene targeting in stem cells from individuals with osteogenesis imperfecta

Adult stem cells offer the potential to treat many diseases through a combination of ex vivo genetic manipulation and autologous transplantation. Mesenchymal stem cells (MSCs, also referred to as marrow stromal cells) are adult stem cells that can be isolated as proliferating, adherent cells from bones. MSCs can differentiate into multiple cell types present in several tissues, including bone, fat, cartilage, and muscle, making them ideal candidates for a variety of cell-based therapies. Here, we have used adeno-associated virus vectors to disrupt dominant-negative mutant COL1A1 collagen genes in MSCs from individuals with the brittle bone disorder osteogenesis imperfecta, demonstrating successful gene targeting in adult human stem cells.     

Hematopoietic histoincompatibility reactions by NK cells in vitro: model for genetic resistance to marrow grafts

In certain strains of mice, bone marrow grafts from parental donors fail to grow in first-generation hybrid mice. This "hybrid resistance" of nonsensitized F1 hybrid mice to the engraftment of parental hematopoietic transplants contradicts the classical laws of transplantation and is dependent on a radioresistant but immunogenetically specific effector mechanism. Studies in a new in vitro model reveal that committed hematopoietic precursors of parental origin can be inactivated by direct contact with natural killer-like splenic effectors from F1 mice. The reaction requires genetically restricted recognition, since only parental competitors syngeneic to the target bone marrow cells partially reversed this inactivation. Models of this type may be useful in studying the possible role of natural resistance in bone marrow transplantation in humans.     

Bone marrow: the bursa equivalent in man?

Human bone marrow lymphoid cells, particularly when enriched with plasma cells, as in multiple myeloma, respond to pokeweed mitogen and to antiserum to immunoglobulin but not to phytohemagglutinin. Cells of patients with X-linked agammaglobulinemia of the bursal deficient type failed to respond to either pokeweed or to the antiserum to immunoglobulin. Leukocytes of the agammaglobulinemia patients however responded in a normal fashion to phytohemagglutinin. Just as the in vitro response to phytohemagglutinin is taken as an index of the thymus-dependent system, the in vitro response to both antiserum to immunoglobulin and pokeweed may be considered an index for the bursaldependent system. Human bone marrow, therefore, contains bursal cells and probably very few or no thymus cells.     

Engraftment and development of human T and B cells in mice after bone marrow transplantation.

A model for human lymphocyte ontogeny has been developed in a normal mouse. Human bone marrow, depleted of mature T and B lymphocytes, and bone marrow from mice with severe combined immunodeficiency were transplanted into lethally irradiated BALB/c mice. Human B and T cells were first detected 2 to 4 months after transplantation and persisted for at least 6 months. Most human thymocytes (30 to 50 percent of total thymocytes) were CD3+CD4+CD8+. Human immunoglobulin was detected in some chimeras, and a human antibody response to dinitrophenol could be generated after primary and secondary immunization.     

基因治疗及其在兽医学中的应用

基因治疗是20世纪90年代形成的，该技术的研究一开始就与动物医学的发展密不可分，主要是通过建立动物疾病模型分析和研究基因治疗各种层面上的问题，但它真正在兽医临床上的研究是近年才开始的。许多试验结果表明，一旦载体的安全性有了保障，基因治疗将有可能成为动物重大疫病有效预防和治疗的方法，在兽医学中有很广阔的应用前景。     

Differentiation of murine bone marrow stem cells in vitro: long-term growth promoted by a lymphocyte-derived mediator

In attempts to induce differentiation of lymphoid cells from hematopoietic stem cells in vitro, the effects of allogeneic effect factor on the growth of murine bone marrow cultures were studied. Allogeneic effect factor is a soluble mediator derived from mixed secondary murine leukocyte cultures. For several weeks it supported the growth of bone marrow cultures, as indicated by the maintenance of stem cell activity, cellular proliferation, and heterogeneity. Another lymphokine, T cell growth factor, did not, Pre-T lymphocytes could be detected in these cultures for several weeks.     

诱导性多能干细胞的研究及应用

自从小鼠的胚胎成纤维细胞和鼠尾成纤维细胞重编程成为诱导多能干细胞（induced pluripotent stem cells,iPSCs）以来,iPS的研究成了干细胞研究领域的热点。与胚胎干细胞相比,iPS细胞有操作简便和高稳定性等优点可以应用于,如创建人类疾病的遗传模型,培育转基因动物用于器官移植,改善动物生产性状和抗病性,以及生物制药等领域。另外,iPSCs的产生对于解决长期以来干细胞研究领域的伦理问题和免疫排斥问题有巨大的意义,iPS结合基因治疗和细胞移植疗法的成果已经应用到了动物疾病模型上。iPS细胞技术给病人特定细胞治疗和基因针对性药品研制带来了巨大的前景。此外,该技术也提供了iPS细胞重编程机制和人类疾病的病理过程研究的新平台。然而,现阶段多能干细胞的研究只是开辟了一个新的领域,iPS技术要应用于临床还有很多工作要做。本文主要针对iPSCs的研究现状与应用前景进行讨论。     

DISSOCIATION OF HOMOGRAFT RESPONSE TO ALLOGENEIC VERSUS XENOGENEIC SKIN GRAFTS IN IRRADIATED MICE

Lethally x-irradiated (C3H x DBA/2)F(1) mice were protected with syngeneic (isogenic) bone marrow and/ or prior treatment with urethan and skin grafted at various times after irradiation. The ability to reject a first-set xenogeneic (heterologous) skin graft with normal vigor returned within 92 days; the first-set response to allogeneic (homologous) grafts was still impaired 350 days after irradiation.     

Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice

Rejection of bone marrow grafts in irradiated mice is mediated by natural killer (NK) cells and is controlled by genes linked to the major histocompatibility complex (MHC). It has, however, not been possible to identify the genes or their products. An MHC class I (Dd) transgene introduced in C57BL donors prevented the rejection of their bone marrow by NK cells in irradiated allogeneic and F1 hybrid mice expressing the Dd gene. Conversely, H-2Dd transgenic C57BL recipients acquired the ability to reject bone marrow from C57BL donors but not from H-2Dd transgenic C57BL donors. These results provide formal evidence that NK cells are part of a system capable of rejecting cells because they lack normal genes of the host type, in contrast to T cells, which recognize cells that contain abnormal or novel sequences of non-host type.